Personalized medicine for non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

被引：0
|
作者：
Hamada, Akinobu
Sasaki, Ji-ichiro
Saeki, Sho
Iwamoto, Norihiro
Inaba, Megumi
Ushijima, Sunao
Urata, Maki
Kishi, Hiroto
Fujii, Shinji
Semba, Hiroshi
Kai, Yuki
Saito, Hideyuki
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3588
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy
    Hsiao, C.
    Kuo, S.
    Chen, K.
    Chen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S474 - S474
  • [42] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer With Uncommon Mutations
    Kanazu, Masaki
    Naoki, Yoko
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Omachi, Naoki
    Okishio, Kyoichi
    Suzuki, Hidekazu
    Okamoto, Norio
    Morishita, Naoko
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S318 - S318
  • [43] Study on the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients
    Chen, Fei
    Li, Hongbo
    Zhang, Huanming
    MINERVA GASTROENTEROLOGY, 2024, 70 (01): : 135 - 137
  • [44] Rebiopsy for Patients with Non-Small Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure
    Li, Xuefei
    Su, Chunxia
    Ren, Shengxiang
    Zhao, Chao
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1256 - S1256
  • [45] A COMPARATIVE STUDY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATMENT OF PATIENTS WITH BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER
    Zhang, L.
    Cai, L.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 421 - 421
  • [46] Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
    Wang Han-ping
    Zhang Li
    Wang Yin-xiang
    Tan Fen-lai
    Xia Ying
    Ren Guan-jun
    Hu Pei
    Jiang Ji
    Wang Meng-zhao
    Xiao Yi
    CHINESE MEDICAL JOURNAL, 2011, 124 (13) : 1933 - 1938
  • [47] The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
    Feng, Yongdong
    Zhu, Guangkuo
    Lang, Song
    Hao, Ping
    Li, Guanghui
    Chen, Fanglin
    Zhuo, Wenlei
    Duan, Yuzhong
    Zhang, Anmei
    Chen, Zhengtang
    Sun, Jianguo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era
    Refeno, Valery
    Lamuraglia, Michele
    Terrisse, Safae
    Bonnet, Clement
    Dumont, Clement
    Doucet, Ludovic
    Pouessel, Damien
    Culine, Stephane
    CANCERS, 2021, 13 (15)
  • [49] Association of tumour CD4 positive lymphocytes with prognosis in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor
    Zhu, Y-J.
    Zhang, H-B.
    Chang, X-S.
    Xiao, Z-Z.
    Liu, L-R.
    Liu, Y-H.
    ANNALS OF ONCOLOGY, 2020, 31 : S290 - S290
  • [50] Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
    De Pas, Tommaso
    Toffalorio, Francesca
    Manzotti, Michela
    Fumagalli, Caterina
    Spitaleri, Gianluca
    Catania, Chiara
    Delmonte, Angelo
    Giovannini, Monica
    Spaggiari, Lorenzo
    de Braud, Filippo
    Barberis, Massimo
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1895 - 1901
12345